サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：アプタマーの世界市場
市場調査レポート
商品コード
1193782

アプタマーの世界市場

Aptamers
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 179 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
アプタマーの世界市場
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のアプタマーの市場規模は、2022年に1億4,650万米ドルとなり、2030年までに4億7,790万米ドルに達し、2022年～2030年にかけてCAGRで15.9%の成長が予測されています。

当レポートでは、世界のアプタマー市場について調査し、市場概要、市場動向と促進要因、市場分析等に関する情報を提供しています。

主要競合企業（全12社）

  • AM Biotechnologies, LLC
  • Aptagen, LLC
  • Aptamer Group
  • Aptamer Sciences Inc.
  • Aptus Biotech
  • Base Pair Biotechnologies, Inc.
  • NeoVentures Biotechnology Inc.
  • SomaLogic, Inc.
  • TriLink BioTechnologies, LLC.
  • Vivonics, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10352

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Aptamers Market to Reach $477.9 Million by 2030

In the changed post COVID-19 business landscape, the global market for Aptamers estimated at US$146.5 Million in the year 2022, is projected to reach a revised size of US$477.9 Million by 2030, growing at a CAGR of 15.9% over the analysis period 2022-2030. DNA Aptamers, one of the segments analyzed in the report, is projected to record a 16% CAGR and reach US$227.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the XNA Aptamers segment is readjusted to a revised 16.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $39.9 Million, While China is Forecast to Grow at 21.3% CAGR

The Aptamers market in the U.S. is estimated at US$39.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$115.1 Million by the year 2030 trailing a CAGR of 21.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.8% and 13.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$74.8 Million by the year 2030.

Select Competitors (Total 12 Featured):

  • AM Biotechnologies, LLC
  • Aptagen, LLC
  • Aptamer Group
  • Aptamer Sciences Inc.
  • Aptus Biotech
  • Base Pair Biotechnologies, Inc.
  • NeoVentures Biotechnology Inc.
  • SomaLogic, Inc.
  • TriLink BioTechnologies, LLC.
  • Vivonics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • An Overview Aptamers
    • Aptamers - Advances and Discoveries
    • Aptamers - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for SELEX by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for SELEX by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 11: World Aptamers Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for DNA Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for DNA Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for XNA Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for XNA Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for RNA Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 17: World 8-Year Perspective for RNA Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Therapeutics Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 19: World 8-Year Perspective for Therapeutics Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 21: World 8-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 23: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 25: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 27: World 8-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 29: USA 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 31: USA 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 35: USA 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Canada 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Canada 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Canada 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • JAPAN
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Japan 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Japan 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Japan 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • CHINA
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 52: China Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 53: China 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 55: China 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 59: China 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • EUROPE
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Aptamers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 61: Europe 8-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Europe 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Europe 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Europe 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • FRANCE
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 71: France 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 73: France 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 77: France 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • GERMANY
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 79: Germany 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Germany 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 85: Germany 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 89: Italy 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 91: Italy 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Italy 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • UNITED KINGDOM
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 94: UK Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 95: UK 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 97: UK 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 99: UK 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 101: UK 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • SPAIN
    • TABLE 102: Spain Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 103: Spain 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 104: Spain Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Spain 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 106: Spain Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 107: Spain 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 108: Spain Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 109: Spain 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • RUSSIA
    • TABLE 110: Russia Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Russia 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 112: Russia Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 113: Russia 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 114: Russia Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 115: Russia 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 116: Russia Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Russia 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 125: Rest of Europe 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 8-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 133: Asia-Pacific 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • AUSTRALIA
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 136: Australia Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 137: Australia 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 138: Australia Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 139: Australia 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 140: Australia Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Australia 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 142: Australia Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 143: Australia 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • INDIA
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 144: India Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 145: India 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 146: India Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 147: India 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 148: India Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 149: India 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 150: India Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 151: India 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • SOUTH KOREA
    • TABLE 152: South Korea Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 153: South Korea 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 154: South Korea Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 155: South Korea 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 156: South Korea Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 157: South Korea 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 158: South Korea Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 159: South Korea 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 160: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 161: Rest of Asia-Pacific 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 162: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 163: Rest of Asia-Pacific 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 164: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of Asia-Pacific 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 167: Rest of Asia-Pacific 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • LATIN AMERICA
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 168: Latin America Recent Past, Current & Future Analysis for Aptamers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 169: Latin America 8-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2023 & 2030
    • TABLE 170: Latin America Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Latin America 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 172: Latin America Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 173: Latin America 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 174: Latin America Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 175: Latin America 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 176: Latin America Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Latin America 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • ARGENTINA
    • TABLE 178: Argentina Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 179: Argentina 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 180: Argentina Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 181: Argentina 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 182: Argentina Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Argentina 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 184: Argentina Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 185: Argentina 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • BRAZIL
    • TABLE 186: Brazil Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 187: Brazil 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 188: Brazil Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Brazil 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 190: Brazil Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 191: Brazil 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 192: Brazil Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 193: Brazil 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • MEXICO
    • TABLE 194: Mexico Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Mexico 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 196: Mexico Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 197: Mexico 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 198: Mexico Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 199: Mexico 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 200: Mexico Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Mexico 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 202: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 203: Rest of Latin America 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 204: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 205: Rest of Latin America 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 206: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Rest of Latin America 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 209: Rest of Latin America 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • MIDDLE EAST
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 210: Middle East Recent Past, Current & Future Analysis for Aptamers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 211: Middle East 8-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2023 & 2030
    • TABLE 212: Middle East Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Middle East 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 214: Middle East Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 215: Middle East 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 216: Middle East Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 217: Middle East 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 218: Middle East Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Middle East 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • IRAN
    • TABLE 220: Iran Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 221: Iran 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 222: Iran Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 223: Iran 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 224: Iran Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 225: Iran 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 226: Iran Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 227: Iran 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • ISRAEL
    • TABLE 228: Israel Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 229: Israel 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 230: Israel Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 231: Israel 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 232: Israel Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 233: Israel 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 234: Israel Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 235: Israel 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • SAUDI ARABIA
    • TABLE 236: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 237: Saudi Arabia 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 238: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 239: Saudi Arabia 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 240: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 241: Saudi Arabia 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 243: Saudi Arabia 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 244: UAE Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 245: UAE 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 246: UAE Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 247: UAE 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 248: UAE Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 249: UAE 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 250: UAE Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 251: UAE 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 252: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 253: Rest of Middle East 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 254: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 255: Rest of Middle East 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 256: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 257: Rest of Middle East 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 259: Rest of Middle East 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030
  • AFRICA
    • Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 260: Africa Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 261: Africa 8-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2023 & 2030
    • TABLE 262: Africa Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 263: Africa 8-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2023 & 2030
    • TABLE 264: Africa Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 265: Africa 8-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2023 & 2030
    • TABLE 266: Africa Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 267: Africa 8-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2023 & 2030

IV. COMPETITION